^
+ Follow ONTARGET Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 134000
                    [Title] => Study centers in 40 countries involved in heart pr
                    [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.
[DatePublished] => 2001-09-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 83550 [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.

The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.
[DatePublished] => 2001-06-18 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
ONTARGET
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 134000
                    [Title] => Study centers in 40 countries involved in heart pr
                    [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.
[DatePublished] => 2001-09-17 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 83550 [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.

The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.
[DatePublished] => 2001-06-18 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with